• Initial management of increased uric acid levels in patients with leukemia, lymphoma, or other malignancies who are being treated with antineoplastics, which are expected to produce hyperuricemia.

Contraindicated in:

• Glucose-6–phosphate dehydrogenase (G6PD) deficiency (↑ risk of severe hemolysis)
• Previous allergic reaction, hemolysis, or methemoglobinemia from rasburicase
• OB: Pregnancy
• Lactation: Lactation.

Use Cautiously in:

• None reported.

Derm: rash.

GI: abdominal pain, constipation, diarrhea, mucositis, nausea, vomiting.

Hemat: HEMOLYSIS, METHEMOGLOBINEMIA, neutropenia.

Neuro: headache.

Resp: respiratory distress.

Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), sepsis.

Drug-Drug:

• None reported.

• Lyophilized powder for injection: 1.5 mg/vial; 7.5 mg/vial;

• IV (Adults and Children): 0.2 mg/kg daily as a single dose for 5 days.

Elitek

• An enzyme that promotes the conversion of uric acid to allantoin, an inactive, water-soluble compound.
• Produced by recombinant DNA technology.

• Decreased sequelae of hyperuricemia (nephropathy, arthropathy).

Therapeutic Classification: antigout agents, antihyperuricemics

Pharmacologic Classification: enzymes

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Unknown.

Half-life: 18 hr.

Fasturtec

(↓ in uric acid)

• Inform patient and family of purpose of rasburicase infusion.
• Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during and for 2 wk after last dose.

ras-BYOOR-i-case

NDC Code^*

• 0024- Sanofi-Aventis U.S. LLC
  • 0024-5150- Elitek
    • 0024-5150-10- 3 KIT in 1 CARTON (0024-5150-10) > 1 KIT in 1 KIT * 1 mL in 1 AMPULE * 1 mL in 1 VIAL, SINGLE-USE

• 0024- Sanofi-Aventis U.S. LLC
  • 0024-5151- Elitek
    • 0024-5151-75- 1 KIT in 1 CARTON (0024-5151-75) * 5 mL in 1 AMPULE * 5 mL in 1 VIAL, SINGLE-USE